Chemestmed has secured a grant of €2 million to complete preclinical studies and move towards clinical trials
We are pleased to announce that Chemestmed has secured a grant of approximately €2 million from the Estonian Business and Innovation Agency for the project titled “Preclinical development of novel first-in-class epitranscriptomic drug candidates against neuropsychiatric disorders”. Combined with Chemestmed’s own contribution, the project budget totals €2.9 million. This funding will support the completion of IND-enabling studies required to move our novel molecule into clinical trials as a potential treatment for conditions such as anxiety and Parkinson’s disease.
The ultimate goal of the project is to develop a first-in-class small-molecule drug designed to repair RNA methylation by restoring normal levels of N6-methyladenosine (m6A). Dysregulation of m6A methylation is implicated in neuropsychiatric disorders and various CNS and metabolic diseases. By advancing this innovative therapy, Chemestmed is paving the way for a completely novel approach to treating these conditions.
Our focus is now on completing key preclinical steps, including dose optimization, GLP toxicity studies, and preliminary GMP studies. These efforts are crucial for advancing the drug into phase I first-in-human clinical trials. The small-molecule drug uniquely targets the METTL3/METTL14/WTAP complex, restoring mRNA methylation levels and increasing cellular m6A. Importantly, the drug is orally administered and demonstrates excellent brain penetration, with animal studies showing significant reductions in anxiety and behavioral improvements without psychostimulant effects.
This project highlights Chemestmed’s leadership in the emerging field of epitranscriptomics, offering the potential to transform the treatment landscape for neuropsychiatric and neurodegenerative disorders and beyond, including conditions like type 2 diabetes. The development will be conducted in collaboration with internationally renowned contract research organizations (CROs) and the University of Tartu, ensuring the highest standards of scientific and clinical excellence.
As we progress, Chemestmed remains committed to transforming therapeutic possibilities and driving innovation in the treatment of debilitating diseases!